Related references
Note: Only part of the references are listed.GBD 2016 Headache Collaborators. Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016 (vol 17, pg 954, 2018)
Ali H. Mokdad
LANCET NEUROLOGY (2021)
Migraine headache: Is it only a neurological disorder? Links between migraine and cardiovascular disorders
Dandan Chen et al.
TRENDS IN CARDIOVASCULAR MEDICINE (2020)
Optimising migraine treatment: from drug-drug interactions to personalized medicine
Leda Marina Pomes et al.
JOURNAL OF HEADACHE AND PAIN (2019)
Delta opioid receptor agonists are effective for multiple types of headache disorders
Laura S. Moye et al.
NEUROPHARMACOLOGY (2019)
Emerging Treatment Targets for Migraine and Other Headaches
Zachariah Bertels et al.
HEADACHE (2019)
Migraine Treatment: Current Acute Medications and Their Potential Mechanisms of Action
Jonathan Jia Yuan Ong et al.
NEUROTHERAPEUTICS (2018)
Role of signalling molecules in behaviours mediated by the delta opioid receptor agonist SNC80
Isaac J. Dripps et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
Tolerance to high-internalizing opioid receptor agonist is critically mediated by arrestin 2
Ana Vicente-Sanchez et al.
BRITISH JOURNAL OF PHARMACOLOGY (2018)
The pathophysiology of migraine: implications for clinical management
Andrew Charles
LANCET NEUROLOGY (2018)
CGRP as the target of new migraine therapies - successful translation from bench to clinic
Lars Edvinsson et al.
NATURE REVIEWS NEUROLOGY (2018)
Global, regional, and national burden of meningitis, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Joseph Raymond Zunt et al.
LANCET NEUROLOGY (2018)
Global, regional, and national burden of migraine and tension-type headache, 1990-2016: a systematic analysis for the Global Burden of Disease Study 2016
Lars Jacob Stovner et al.
LANCET NEUROLOGY (2018)
Targeting delta opioid receptors for pain treatment: drugs in phase I and II clinical development
Viola Spahn et al.
EXPERT OPINION ON INVESTIGATIONAL DRUGS (2017)
Delta opioid receptors expressed in forebrain GABAergic neurons are responsible for SNC80-induced seizures
Paul Chu Sin Chung et al.
BEHAVIOURAL BRAIN RESEARCH (2015)
Why pharmacokinetic differences among oral triptans have little clinical importance: a comment
Anna Ferrari et al.
JOURNAL OF HEADACHE AND PAIN (2011)
Electroencephalographic and convulsant effects of the delta opioid agonist SNC80 in rhesus monkeys
Ingela Danielsson et al.
PHARMACOLOGY BIOCHEMISTRY AND BEHAVIOR (2006)
Share Paper
